drugset / Trial / NCT01922258

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT01922258

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type

Timeline

Start
2013-09
Primary completion
2017-03
Completion
2017-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 0.5 mg
Subject Brexpiprazole Small molecule 1 mg
Subject Brexpiprazole Small molecule 2 mg